Furthermore, the results suggest that all these markers should be used in the earlier stages of the disease, since an analysis of BRCA patients indicated that the FGF2, FGFBP1, TGFA, TGFBR3, and IGF1R gene expression levels were present in late stages 3 and 4 of breast cancer. This evidence concerns the gene FGFBP1 and breast cancer.